Le Lézard
Classified in: Health, Business
Subject: ACC

Hadean Ventures Announces the 1st Closing of EUR 90m for its Second Fund


OSLO, Norway, Sept. 27, 2021 /PRNewswire/ -- Hadean Ventures, a European life science fund manager, today announced the 1st closing of Hadean Capital II at EUR 90m, exceeding the total size of its inaugural fund, Hadean Capital I. The launch comes on the back of strong performance of Hadean Capital I, including the sale of Themis Bioscience GmbH to MSD/Merck.

Hadean Capital II will be investing in line with the strategy of Hadean Capital I, including in start-up companies within pharma, biotech, medtech diagnostics and digital health. The geographic focus will mainly be on European companies, with a particular attention to areas considered "under-ventured" such as the Nordics and certain regions of DACH.

Hadean Capital II is supported by over 30 private and institutional investors including OPF, Saminvest, Argentum and Investinor.

Ingrid Teigland Akay, MD MBA, Managing Partner, commented: "It is a pleasure to welcome new and returning investors to Hadean Capital II. We are excited to continue to support start-up founders who build companies to bring break-through medical innovation to the market."  

Walter Stockinger, PhD, Managing Partner, added: "We are pleased to see that the strategy we set out for our first fund is delivering and we are confident that our growing team of highly skilled and diverse investment professionals will be able to leverage the untapped potential we see in the European life science ecosystem."

About Hadean Ventures

Hadean Ventures is a life science fund manager that invests in life science companies across Europe. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in Oslo and Stockholm and collaborates with world-class academic institutions and start-up hubs across the region.

Contact

Ingrid Teigland Akay, Managing Partner
[email protected]

Ingrid Beyer, Head of IR and Business Development
[email protected]
+47 905 94882

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hadean-ventures-as/r/hadean-ventures-announces-the-1-st--closing-of-eur-90m-for-its-second-fund,c3422389

The following files are available for download:

https://mb.cision.com/Main/20971/3422389/1473779.pdf

Press release (PDF)

https://news.cision.com/hadean-ventures-as/i/hadean-logo-fit-hires,c2960059

Hadean Logo Fit hires

SOURCE Hadean Ventures AS


These press releases may also interest you

at 12:48
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

at 11:55
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...



News published on and distributed by: